Small companies lead the I-O class of Cancer Therapies
ACCESSWIRE - Fri Aug 08, 7:02AM CDT
Los Angeles, CA / August 8, 2014 / Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades. Only recently, immuno-oncology, labeled 'I-O' first by Bristol-Myers Squibb Company (NYSE:BMY) has emerged to become a new class of cancer medicines that may someday take a meaningful place alongside chemotherapy, surgery, and radiation.
CLSN: 2.39 (+0.06), NWBO: 5.58 (+0.04), CVM: 0.62 (+0.03), CLDX: 17.08 (-0.18), INCY: 71.57 (+1.99), AZN: 70.44 (+0.26), MRK: 57.46 (+0.25), DNDN: 0.13 (-0.02), NLNK: 39.08 (+1.36), PPHM: 1.40 (+0.01), BMY: 59.15 (-0.01), FPRX: 26.12 (+0.07)
PUBLICATION IN ACCORDANCE WITH ARTICLE 15 OF THE BELGIAN LAW OF 2 MAY 2007 ON THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW"
GlobeNewswire - Thu Jul 03, 11:07AM CDT
Ablynx [Euronext Brussels: ABLX] announces that the closing of its private placement ("Accelerated Bookbuild Offering"/"ABO"